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Somatic mutations and pretransplant strategy both impact the out-
come of patients with myelodysplastic syndromes (MDS), and acute
myeloid leukemia derived from MDS (sAML) after allogeneic hemato-
poietic stem cell transplantation (allo-HSCT). While the prognostic
influence of several somatic mutations, especially TP53, as a disease-
related variable is established,1 the optimal pretransplant strategy is
less well defined due to the lack of prospective trials. In a recent anal-
ysis we showed that outcome after direct, so called upfront transplan-
tation is at least not inferior compared to pretransplant cytoreduction,
with AML-like induction chemotherapy (CTX) or hypomethylating
agents (HMA).2 In the current analysis we aimed to comprehensively
investigate the interplay of mutations and pretransplant strategy on
outcome after allo-HSCT within one analysis. For this purpose, we
examined pretransplant DNA samples from 128 of the 165 previously
published patients with MDS (n = 97, 76%), sAML (n = 20, 15%) or
chronic myelomonocytic leukemia (n = 11, 9%) for somatic mutations
in 54 genes using the TruSight Myeloid panel (Illumina, San Diego,
CA). Patients' characteristics, sequencing analysis and statistics are
given in Tables S1-S4. Of these, 73 patients (57%) were transplanted
without prior cytoreduction (upfront group), whereas 55 (43%, treat-
ment group) had received either anthracycline-containing induction
(n = 37, 29%, CTX group) or a median of four cycles (range: one to
eight cycles) of Azacitidine (Aza, n = 18 14%, Aza group) prior trans-
plant (Figure S1). Even though there was a higher frequency of sAML
in the CTX group and a lower BM blast count in the upfront group at
diagnosis, progression to advanced disease or even sAML between
diagnosis and transplantation occurred in 14 (19%) and 7 (10%)
patients within the upfront group (median 6.4 months; Tables S1 and
S3). Consequently, at the time of cytoreductive treatment there was
no statistically significant difference regarding the frequency of sAML
between the upfront and treated group (15% vs 29%). With a median
follow-up of 71 months estimated 5-year OS, RFS, CIR, and non-
relapse mortality (NRM) probabilities of the entire cohort were 56%,
42%, 40% and 18%, respectively (Figure S2).
First, we performed amplicon-based sequencing to adress the
prognostic impact of somatic mutations. Hereby, we identified
285 mutations which affected 36 of the 54 investigated genes in
111 of 128 patients (87%, median two mutations per patient, range,
zero to six) and reflected the clinical high-risk characteristics with
RUNX1, TET2, ASXL1, TP53, SRSF2 and DNMT3A representing the most
commonly mutated genes (Figures S3-S7; Table S5). With exception for
RUNX1, TET2 and ASXL1, the mutation profile did not differ between
treatment groups, even when focusing only on MDS patients
(Figure S6, S8, S9). In those 17 genes mutated in ≥5% of patients we
identified mutations in four individual genes (TP53, SF3B1, NRAS and
DNMT3A), which negatively impacted OS and RFS (Figure 1A; Table S6,
Figures S10-S12). Mutations in TP53 and SF3B1 were also associated
with higher relapse incidence, while NRAS and SF3B1 mutations nega-
tively influenced NRM (Table S7; Figure S13-S15). Consequently, muta-
tions in these four genes, which were mutually exclusive to each other
in three of four genes (TP53, NRAS, SF3B1), were summarized as poor-
risk mutations for further analyses (Table S6-S8; Figures S16-S17).
Acknowledging the negative prognostic impact of complex karyotype
(CK, n = 25, Figure S18; Table S9) and the overlap between CK and
poor-risk mutations (Figure S16), we analyzed their prognostic
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interaction. In accordance with recently reported findings3,4 we show
that the presence of poor risk mutations facilitates refinement of the
prognostic information of CK with a dismal prognosis in patients carry-
ing both CK and poor-risk mutations (Figure S19).
Focusing in a next step on other disease-related, patient-
associated and transplant-related factors (Tables S9,S10; Figures S20-
S23) we found that pretransplant strategy was the most prominent
factor significantly influencing OS. Patients, who were transplanted
F IGURE 1 Effects of “poor risk mutations”
and pretransplant strategy on posttransplant
outcome. A, Illustrates posttransplant relapse-
free and overall survival depending on “poor
risk mutation” status and pretransplant strategy
as well as the interplay between both
parameters. B, Illustrates effects of “poor risk
mutation” status and pretransplant strategy on
outcome after HMA-based salvage therapy for
posttransplant relapse in terms of complete
remission rate and overall survival in
41 relapsed patients. “Poor-risk mutation”
status and pretransplant strategy are depicted
in indicated colors and line pattern respectively.
Hazard ratios are relative to those patients
without any poor risk mutation and relative to
those receiving upfront transplantation,
respectively. Allo-HSCT, allogeneic
hematopoietic stem cell transplantation; CR,
complete remission; HMA, hypomethylating
agents; HR, hazard ratio; mut, mutation
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without prior cytoreduction, had longer survival compared to patients
who received pretransplant cytoreduction (Figure 1A, Figure S15). In
addition, patients undergoing upfront transplant had a trend towards
a lower relapse rate (Figure 1A). Except for age (OS and RFS) and CK
(RFS) no other factor impacted OS, RFS, relapse incidence or NRM
(Tables S9-S10; Figures S20-S23).
In multivariate analyses the presence of poor-risk mutations as
well as pretransplant strategy confirmed their prognostic role with
poor-risk mutation carriers and pretreated patients having inferior sur-
vival and higher risk of relapse. Additionally, BCOR and EZH2 muta-
tions were associated with relapse and NRAS and SF3B1 mutations
with NRM (Tables S11-S13).
Based on this, we addressed the hypothesis that there might be
an interaction between these two disease-related and procedure-
related factors and re-analyzed our cohort by combining the informa-
tion about mutation status of these four genes and pretransplant
strategy (Figure 1A). Indeed, the outcome of patients with poor-risk
mutations, who had received pretransplant therapy, was poor with
5-year OS and RFS of 23% and 5.7% and significantly inferior com-
pared to patients with poor-risk mutations in the upfront group
(5-year OS: 45%, 5-year RFS: 27%). In contrast, among patients with-
out poor-risk mutations the upfront group had a favorable 5-year OS
of 83% compared to 62% in pretreated patients, while 5-year RFS
was comparable (5-year RFS 61% vs 54%). These data were confirmed
by a separate analysis of patients with MDS (Figure S24).
Relapse, mainly driven by poor-risk mutations and pretransplant
strategy (Table S12), was the major cause of treatment failure
(Figure S2) with 62% of deaths being attributable to relapse. There-
fore, we finally asked whether these two variables also influenced
response to and survival following salvage therapy with HMA (Aza
n = 40, decitabine n = 1) and donor lymphocytes infusions (DLI,
Figure S25; Table S14). The negative prognostic impact of poor-risk
mutations was indeed abrogated after salvage therapy, as indicated
by a comparable CR rate (43% vs 53%) and survival (2-year OS 43%
vs 53%) in mutation carriers and patients without poor-risk muta-
tions. In contrast, the CR rate was significantly higher (73% vs 21%)
and survival (2-year OS 69% vs 27%) significantly longer in the
upfront group compared to pretreated patients (Figure 1B,
Figure S26).
A major criticism of our previous analysis, where we adressed the
role of upfront transplantation in 165 patients with MDS and sAML,2 is a
possible selection bias where poor-risk patients receive pretransplant
cytoreduction whereas „better-risk “patients may be scheduled for
upfront transplantation. To overcome this we now focused on the
underlying disease biology in terms of somatic mutations in 128 of the
previous cohort,2 which were selected based on DNA availability and
exhibited comparable pretransplant CR rate and survival like the entire
cohort (data not shown). We identified mutations in four genes (TP53,
DNMT3A, NRAS and SF3B1) that were associated with poor post-
transplant outcome primarily related to a higher relapse incidence. Our
data regarding TP53, the NRAS/RAS pathway and in parts DNMT3A
mutations are consistent with results from six other retrospective
analyses in 62 to 1514 patients,1,3-5 with discrepancies between the ana-
lyses probably related to imbalances regarding patient characteristics,
treatment state, sampling and sequencing. The second major finding of
our current, even though retrospective analysis, which also proved true
when considering only the 97 MDS patients, is that upfront transplanta-
tion resulted in a significantly better survival. This is in line with previous
retrospective analyses suggesting at least non-inferiority of upfront
transplantation compared to pretransplant cytoreduction.2 By integrating
molecular information and pretransplant strategy, we here show that
patients with similar disease biology, namely poor-risk mutations have
dismal outcome after pretransplant cytoreduction and seem to benefit
from direct transplantation. It remains unclarified at this point, whether
dose-intensification of conditioning regimen as another procedure-
related, per-se modifiable variable may influence the prognosis associ-
ated with individual mutations such as RAS or TP53 mutations, as
suggested by one,5 but not confirmed in our (Figure S27) and another
analysis.3 Furthermore, whether pretransplant implementation of novel
compounds like CPX-351, venetoclax or APR-246 may overcome
chemoresistance implicated by the four poor-risk mutations will be sub-
ject of future investigations.
Besides the trend towards a lower relapse rate the advantage
of upfront transplantation in the entire, as well as in the molecu-
larly defined poor-risk group, appears to result particularly from a
higher efficacy of salvage therapy with HMA and DLI. A hypothe-
sis explaining this phenomenon may be a Darwinian mechanism
which selects resistant leukemic clones during pretransplant cyto-
reduction resulting in resistant relapse after transplant,6 but
requires prospective confirmation by longitudinal sampling. In
addition to disease burden and diagnosis of MDS previously
reported as predictors for response and survival after post-
transplant therapy with Aza, we here show for the first time that
the pretransplant strategy, but not the four poor-risk mutations
(Figure 1B, Figure S26 and S28) predict response and survival
after HMA-based salvage therapy. We conclude that an individu-
alized allografting concept for patients with MDS should incorpo-
rate molecular profiling at the time of decision for allo-SCT, and
planning of pretransplant strategy. If feasible, upfront transplanta-
tion appears to be associated with favorable outcome particularly
in patients with high-risk molecular characteristics and may be
augmented by post-transplant HMA-based salvage therapy in case
of relapse. These data build the hypothesis and rationale for con-
firmatory testing within a prospective study.
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An evaluation of no-treatment




The standard treatment for acute myeloid leukemia (AML) consists of
induction chemotherapy, followed by consolidation chemotherapy ±
allogeneic hematopoietic stem cell transplantation (HSCT). The
median age of AML is 68 to 70 years. Most older patients are unfit for
such intensive treatments, owing to co-morbidities and frailty. For
such patients, palliative chemotherapy with hypomethylating agents
(HMA) or low-dose cytarabine (LDAC) have usually been offered.
There has been increasing interest in real-world data in AML
which reflect treatments and outcomes in unselected patient
populations. Recent real-world registry data from Europe have
reported that a significant proportion of older patients do not receive
any anti-leukemic therapy at the time of diagnosis, other than best
supportive case (BSC).1-3 However, there has been a paucity of
reported analysis on why such patients do not receive treatment. In
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